Mobile

A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Car...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-023819-34

A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Carcinoma Syndrome

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To evaluate the efficacy of LDE225, as assessed by clinical clearance of a main target BCC (one per patient) in Nevoid Basal Cell Carcinoma Syndrome (NBCCS) patients

Critère d'inclusion

  • Nevoid Basal Cell carcinoma syndrome

Liens